ALEMBIC PHARMA | PANACEA BIOTECH | ALEMBIC PHARMA/ PANACEA BIOTECH |
|||
---|---|---|---|---|---|
P/E (TTM) | x | 19.2 | 9.4 | 204.4% | View Chart |
P/BV | x | 7.4 | 3.7 | 202.5% | View Chart |
Dividend Yield | % | 0.5 | 0.0 | - |
![]() ![]() |
EQUITY SHARE DATA | |||||
---|---|---|---|---|---|
ALEMBIC PHARMA Mar-19 |
PANACEA BIOTECH Mar-19 |
ALEMBIC PHARMA/ PANACEA BIOTECH |
5-Yr Chart Click to enlarge
|
||
High | Rs | 664 | 354 | 187.8% | |
Low | Rs | 412 | 138 | 298.4% | |
Sales per share (Unadj.) | Rs | 208.7 | 74.6 | 279.9% | |
Earnings per share (Unadj.) | Rs | 31.0 | 6.7 | 464.1% | |
Cash flow per share (Unadj.) | Rs | 37.1 | 15.5 | 239.5% | |
Dividends per share (Unadj.) | Rs | 5.50 | 0 | - | |
Dividend yield (eoy) | % | 1.0 | 0 | - | |
Book value per share (Unadj.) | Rs | 144.2 | 57.2 | 252.1% | |
Shares outstanding (eoy) | m | 188.52 | 61.25 | 307.8% | |
Bonus/Rights/Conversions | - | - | - | ||
Price / Sales ratio | x | 2.6 | 3.3 | 78.2% | |
Avg P/E ratio | x | 17.4 | 36.8 | 47.2% | |
P/CF ratio (eoy) | x | 14.5 | 15.9 | 91.4% | |
Price / Book Value ratio | x | 3.7 | 4.3 | 86.8% | |
Dividend payout | % | 17.7 | 0 | - | |
Avg Mkt Cap | Rs m | 101,461 | 15,061 | 673.7% | |
No. of employees | `000 | NA | 2.3 | 0.0% | |
Total wages/salary | Rs m | 7,467 | 1,471 | 507.7% | |
Avg. sales/employee | Rs Th | NM | 1,973.6 | - | |
Avg. wages/employee | Rs Th | NM | 635.6 | - | |
Avg. net profit/employee | Rs Th | NM | 176.8 | - |
INCOME DATA | |||||
---|---|---|---|---|---|
Net Sales | Rs m | 39,347 | 4,567 | 861.5% | |
Other income | Rs m | 94 | 45 | 209.4% | |
Total revenues | Rs m | 39,441 | 4,612 | 855.2% | |
Gross profit | Rs m | 8,736 | 2,030 | 430.4% | |
Depreciation | Rs m | 1,152 | 540 | 213.4% | |
Interest | Rs m | 184 | 1,048 | 17.6% | |
Profit before tax | Rs m | 7,493 | 486 | 1,541.2% | |
Minority Interest | Rs m | 11 | 0 | - | |
Prior Period Items | Rs m | -93 | 0 | - | |
Extraordinary Inc (Exp) | Rs m | 0 | 0 | - | |
Tax | Rs m | 1,568 | 77 | 2,033.1% | |
Profit after tax | Rs m | 5,844 | 409 | 1,428.4% | |
Gross profit margin | % | 22.2 | 44.4 | 50.0% | |
Effective tax rate | % | 20.9 | 15.9 | 131.9% | |
Net profit margin | % | 14.9 | 9.0 | 165.8% |
BALANCE SHEET DATA | |||||
---|---|---|---|---|---|
Current assets | Rs m | 19,577 | 2,415 | 810.8% | |
Current liabilities | Rs m | 14,896 | 9,077 | 164.1% | |
Net working cap to sales | % | 11.9 | -145.9 | -8.2% | |
Current ratio | x | 1.3 | 0.3 | 494.1% | |
Inventory Days | Days | 90 | 65 | 137.9% | |
Debtors Days | Days | 45 | 71 | 64.0% | |
Net fixed assets | Rs m | 27,097 | 8,333 | 325.2% | |
Share capital | Rs m | 377 | 61 | 615.0% | |
"Free" reserves | Rs m | 26,811 | 3,443 | 778.8% | |
Net worth | Rs m | 27,188 | 3,504 | 775.9% | |
Long term debt | Rs m | 4,993 | 461 | 1,082.6% | |
Total assets | Rs m | 47,778 | 13,755 | 347.3% | |
Interest coverage | x | 41.7 | 1.5 | 2,848.9% | |
Debt to equity ratio | x | 0.2 | 0.1 | 139.5% | |
Sales to assets ratio | x | 0.8 | 0.3 | 248.0% | |
Return on assets | % | 12.6 | 10.6 | 119.1% | |
Return on equity | % | 21.5 | 11.7 | 184.1% | |
Return on capital | % | 23.6 | 38.7 | 61.0% | |
Exports to sales | % | 0 | 20.9 | 0.0% | |
Imports to sales | % | 0 | 8.1 | 0.0% | |
Exports (fob) | Rs m | NA | 954 | 0.0% | |
Imports (cif) | Rs m | NA | 372 | 0.0% | |
Fx inflow | Rs m | 19,453 | 1,203 | 1,617.0% | |
Fx outflow | Rs m | 6,065 | 467 | 1,299.6% | |
Net fx | Rs m | 13,388 | 736 | 1,818.1% |
CASH FLOW | |||||
---|---|---|---|---|---|
From Operations | Rs m | 8,120 | 1,049 | 774.2% | |
From Investments | Rs m | -7,556 | -54 | 14,123.4% | |
From Financial Activity | Rs m | 590 | -1,011 | -58.4% | |
Net Cashflow | Rs m | 1,153 | -20 | -5,854.3% |
Indian Promoters | % | 74.1 | 74.5 | 99.5% | |
Foreign collaborators | % | 0.0 | 0.0 | - | |
Indian inst/Mut Fund | % | 2.9 | 0.6 | 483.3% | |
FIIs | % | 9.1 | 1.3 | 700.0% | |
ADR/GDR | % | 0.0 | 0.0 | - | |
Free float | % | 13.9 | 23.6 | 58.9% | |
Shareholders | 49,328 | 10,259 | 480.8% | ||
Pledged promoter(s) holding | % | 0.0 | 35.1 | - |
Compare ALEMBIC PHARMA With: CADILA HEALTHCARE TTK HEALTHCARE NEULAND LABS BIOCON J.B.CHEMICALS
Compare ALEMBIC PHARMA With: ADCOCK INGRAM (S. Africa) MYLAN (US) ACTAVIS (US) TEVA PHARMA (Israel)
Indian share markets witnessed huge selling pressure today, in line with global equities and fell on to bearish territory.
The BSE HEALTHCARE Index Down at 22,079 (down 2.0%). Among the top losers in the BSE HEALTHCARE Index today are DISHMAN CARBOGEN AMCIS, JUBILANT LIFE SCIENCES and SHALBY . Meanwhile, the BSE Sensex has plunged 0.6% to 49,122.
For the quarter ended September 2020, ALEMBIC PHARMA has posted a net profit of Rs 3 bn (up 30.0% YoY). Sales on the other hand came in at Rs 15 bn (up 17.4% YoY). Read on for a complete analysis of ALEMBIC PHARMA's quarterly results.
For the quarter ended December 2019, ALEMBIC PHARMA has posted a net profit of Rs 2 bn (up 33.3% YoY). Sales on the other hand came in at Rs 12 bn (up 18.8% YoY). Read on for a complete analysis of ALEMBIC PHARMA's quarterly results.
For the quarter ended September 2019, ALEMBIC PHARMA has posted a net profit of Rs 3 bn (up 25.2% YoY). Sales on the other hand came in at Rs 12 bn (up 10.1% YoY). Read on for a complete analysis of ALEMBIC PHARMA's quarterly results.
For the quarter ended June 2019, ALEMBIC PHARMA has posted a net profit of Rs 1 bn (up 36.4% YoY). Sales on the other hand came in at Rs 9 bn (up 10.0% YoY). Read on for a complete analysis of ALEMBIC PHARMA's quarterly results.
More Views on NewsMy new guide will show you the huge potential in future proof businesses.
The smallcap rally has enough steam left in it. If you haven't joined yet, it is still not too late.
The charts are telling the bulls to be cautious.
Were you shocked that bullion prices hit lower circuits on Friday on the MCX? Find out why it happened...
More